Live feed16:00:00·6dPRReleaseAcrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development OpportunitiesACRV· Acrivon Therapeutics Inc.Health CareOriginal source
